|Mr. Leon O. Moulder Jr., M.B.A.||Co-Founder, Chief Exec. Officer and Director||1.09M||N/A||60|
|Dr. Mary Lynne Hedley Ph.D.||Co-Founder, Pres, Chief Operating Officer and Director||1.01M||N/A||54|
|Mr. Timothy R. Pearson||Chief Financial Officer and Exec. VP||646.76k||N/A||49|
|Mr. Jeffrey H. Hanke Ph.D.||Chief Scientific Officer and Exec. VP of R&D||703.97k||862.44k||60|
|Dr. Martin H. Huber Jr., M.D.||Chief Medical Officer and Sr. VP||732.52k||N/A||57|
Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It markets Rolapitant, a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting under the VARUBI brand name. The company is also developing Niraparib, an orally active and potent poly polymerase inhibitor, which is in various clinical trials to treat ovarian or breast cancers. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in pre-clinical research stage targeting lymphocyte-activation gene-3. It has license and collaboration agreements with AnaptysBio, Inc.; and The University of Texas MD Anderson Cancer Center, as well as with Janssen Biotech, Inc., Zai Lab (Shanghai) Co., Ltd, and OPKO Health, Inc. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Tesaro, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 2. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 3; Compensation: 4.